A case-matched molecular comparison of extraovarian versus primary ovarian adenocarcinoma

Cancer

Volumn 79, Issue 8, 1997, Pages 1587-1594

  Kowalski, Lynn D ^a,c   Kanbour, Anisa I ^a   Price, Fredric V ^a   Finkelstein, Sydney D ^a   Christopherson, Wayne A ^a   Seski, Jan C ^b   Naus, Gregory J ^a   Burnham, Judith A ^a   Kanbour Shakir, Amal ^a   Edwards, Robert P ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

aneuploidy; c erb B 2 protooncogene protein; flow cytometry; immunohistochemistry; ovarian neoplasms; p53 protein; peritoneal neoplasms

Indexed keywords

ONCOPROTEIN; PROTEIN P53;

ADULT; AGED; ANEUPLOIDY; ARTICLE; CANCER GRADING; CLINICAL ARTICLE; CONTROLLED STUDY; DNA CONTENT; FEMALE; FLOW CYTOMETRY; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALIGNANT TRANSFORMATION; MISSENSE MUTATION; MIXED MULLERIAN TUMOR; MOLECULAR GENETICS; ONCOGENE NEU; OVARY ADENOCARCINOMA; PRACTICE GUIDELINE; PRIORITY JOURNAL;

ADENOCARCINOMA, CLEAR CELL; ADENOCARCINOMA, MUCINOUS; ADULT; AGED; ANEUPLOIDY; CARCINOMA, ENDOMETRIOID; CASE-CONTROL STUDIES; CYSTADENOCARCINOMA, PAPILLARY; FEMALE; GENES, P53; HUMANS; MIDDLE AGED; NEOPLASM PROTEINS; NEOPLASM STAGING; OMENTUM; OVARIAN NEOPLASMS; PERITONEAL NEOPLASMS; RECEPTOR, ERBB-2; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0030900215     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19970415)79:8<1587::AID-CNCR22>3.0.CO;2-T     Document Type: Article

References (44)

1. Killackey M, Davis AR. Papillary serous carcinoma of the peritoneal surface: matched-case comparison with papillary serous ovarian carcinoma. Gynecol Oncol 1993;51:171-4.
2. Fromm GL, Gershenson DM, Silva EG. Papillary serous carcinoma of the peritoneum. Obstet Gynecol 1990;74:89-95.
3. Bloss JD, Liao S-Y, Buller RE, Manetta A, Herman ML, McMeekin S, et al. Extraovarian peritoneal serous papillary carcinoma: a case-control retrospective comparison to papillary adenocarcinoma of the ovary. Gynecol Oncol 1993; 50:347-51.
4. Altaras MM, Aviram R, Cohen I, Cordoba M, Weiss E, Beyth Y. Primary peritoneal papillary serous adenocarcinoma: clinical and management aspects. Gynecol Oncol 1991; 40:230-6.
5. Stenchever M. Embryology. In: Droegemueller W et al., editors. Comprehensive gynecology. St. Louis: C.V. Mosby Company, 1988:11-8.
6. Fearon E, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990;61:759-67.
7. Gullick WJ. The role of the epidermal growth factor receptor and the c-erbB-2 protein in breast cancer. Int J Cancer 1990; (Supp 5):55-61.
8. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989;244:707-12.
9. Hudziak RM, Schlessinger J, Ullrich A. Increased expression of the putative growth factor receptor p185HER2 causes transformation and tumorigenesis of NIH 3T3 cells. Proc Natl Acad Sci USA 1987;84:7159-63.
10. DiFiore PP, Pierce JH, Fleming TP, Hazan R, Ullrich A, King CR, et al. Overexpression of the human EGF receptor confers an EGF-dependent transformed phenotype to NIH 3T3 cells. Cell 1987;51:1063-70.
11. Berchuk A, Kamel A, Whitaker R, Kerns B, Olt G, Kinney R, et al. Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer. Cancer Res 1990;50:4087-91.
12. Corbett IP, Henry JA, Angus B, Watchorn CJ, Wilkinson L, Hennessy C, et al. NCL-CB11, a new monoclonal antibody recognizing the internal domain of the c-erb B-2 oncogene protein effective for use on formalin-fixed, paraffin-embedded tissue. J Pathol 1990;161:15-25.
13. Greenblatt MS, Bennett WP, Hollstein M, Harris CC. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 1994; 54:4855-78.
14. Finlay CA, Hinds PW, Tan T-H. Activating mutations for transformation by p53 produce a gene product that forms an hsc70-p53 complex with an altered half-life. Mol Cell Biol 1988;8:531-9.
15. Kupryjanczyk J, Thor AD, Beauchamp R, Merritt V, Edgerton SM, Bell DA, et al. p53 gene mutations and protein accumulation in human ovarian cancer. Proc Natl Acad Sci USA 1993;90:4961-5.
16. Kihana T, Tsuda H, Teshima S, Okada S, Matsuura S, Hirohashi S. High incidence of p53 gene mutation in human ovarian cancer and its association with nuclear accumulation of p53 protein and tumor DNA aneuploidy. Jpn J Cancer Res 1992;83:978-84.
17. Marks JR, Davidoff AM, Kerns BJ, Humphrey PA, Pence JC, Dodge RK, et al. Overexpression and mutation of p53 in epithelial ovarian cancer. Cancer Res 1991;51:2979-84.
18. Naus GJ. Cytophotometric DNA content analysis in malignancies of the female genital tract. In: Sciarra JJ, editor. Gynecology and obstetrics. Philadelphia: J.B. Lippincott, 1990:1-9.
19. Hall PA, Lane DP. p53 in tumour pathology: can we trust immunohistochemistry?-revisited! J Pathol 1994;172:1-4.
20. Finkelstein S, Przygodzki R, Pricolo V. p53/K-ras-2 topographic genotyping of colorectal adenocarcinoma. Mol Diag 1996;1:5-28.
21. Naus G, Simmerman R. Prognostic value of flow cytophotometric DNA content analysis in single treatment stage IB to IIA squamous cell carcinoma of the cervix. Gynecol Oncol 1991;43:149-53.
22. Henriksen R, Strang P, Wilander E, Backstrom T, Tribukait B, Oberg K. p53 expression in epithelial ovarian neoplasms: relationship to clinical and pathological parameters, Ki-67 expression, and flow cytometry. Gynecol Oncol 1994;53:301-6.
23. Milner BJ, Allan LA, Eccles DM, Kitchener HC, Leonard RCF, Kelly KF, et al. p53 mutation is a common event in ovarian carcinoma. Cancer Res 1993;53:2128-32.
24. Deshane J, Siegal GP, Alvarez RD, Wang M, Cabrera G, Feng M, et al. A strategy to accomplish gene therapy for ovarian carcinoma based upon targeted tumor cell killing via an intracellular antibody directed against the erB-2 oncoprotein. Gynecol Oncol 1996;60(A):115-16.
25. Hung MC, Matin A, Zhang Y, Xing X, Sorgi F, Huang L. HER-2/neu-targeting gene therapy-a review. Gene 1995;159:65-71.
26. Bookman M, Karlan B, Birrer M. A Phase II evaluation of anti-HER2 antibody in recurrent or refractory ovarian cancer. Protocol GOG #160. Gynecology Oncology Group 1996.
27. Pietras RJ, Fendly BM, Chazin VR, Pegram MD, Howell SB, Slamon DJ. Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells. Oncogene 1994;9:1829-38.
28. c-erB-2 signaling enhances cisplatin-induced cytotoxicity in human breast carcinoma cells: association between an oncogenic receptor tyrosine kinase and drug-induced DNA repair. Cancer Res 1994;54:3758-65.
29. Yu D, Hung M-C. Expression of activated rat neu oncogene is sufficient to induce experimental metastasis in 3T3 cells. Oncogene 1991;6:1991-6.
30. Yu D, Hamada J, Zhang H, Nicolson GL, Hung M-C. Mechanisms of c-erb B2/neu oncogene-induced metastasis and repression of metastatic properties by adenovirus 5 E1A gene products. Oncogene 1992;7:2263-70.
31. Yu D, Wang S-S, Dulski KM, Tsai C-M, Nicolson GL, Hung M-C. C-erbB-2/neu overexpression enhances metastatic potential of human lung cancer cells by induction of metastasis-associated properties. Cancer Res 1994;54:3260-6.
32. Bloss J. GOG Protocol #138: Phase II clinical trial of cisplatinum and cytoxan in extraovarian serous adenocarcinoma. Gynecologic Oncology Group Protocol 1995.
33. Eltabbakh G, Belinson J, Kennedy A, Biscotti C, Casey G, Tubbs R. p53 expression in primary epithelial ovarian carcinoma: relationship to age and survival. Gynecol Oncol 1996; 60(A):146.
34. Ikenberg H, Hollerbach E, Sauerbrei W, Pfisterer J, Kommoss F, Kiechle M, et al. p53 protein overexpression is not associated with poor prognosis in patients with ovarian carcinoma. Gynecol Oncol 1996;60(A):155.
35. Cross SM, Sanchez CA, Morgan CA, Schimke MD, Ramel S, Edzerda RL, et al. A p53-dependent mouse spindle checkpoint. Science 1995;267:1353-6.
36. Livingstone LR, White A, Sprouse J, Livanos E, Jacks T, Tisty T. Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53. Cell 1992;70:923-35.
37. Tavassoli M, Steingrimsdottir H, Pierce E, Hiang X, Alagoz M, Farzaneh F, et al. Loss of heterozygosity on chromosome 5q in ovarian cancer is frequently accompanied by TP53 mutation and identifies a tumour suppressor gene locus at 5q13.1-21. Br J Cancer 1996;74:115-9.
38. Gabra H, Watson J, Taylor K, MacKay J, Leonard R, Steel C, et al. Definition and refinement of a region of loss of heterozygosity at 11q23.3-q24.3 in epithelial ovarian cancer associated with poor prognosis. Cancer Res 1996;56:950-4.
39. Chen K, Hsieh T, Schwartz P, Yang-Feng T. Allelic deletion mapping of putative tumor suppressor genes on 17q in sporadic ovarian cancer. J Obstet Gynecol 1995;21:619-24.
40. Yang-Feng T, Han H, Chen K, Li S, Claus E, Carcangiu M, et al. Allelic loss in ovarian cancer. Int J Cancer 1993;54:546-51.
41. Devlin J, Elder P, Gabra H, Steel C, Knowles M. High frequency of chromosome 9 deletion in ovarian cancer: evidence for three tumour-suppressor loci. Br J Cancer 1996; 73:420-3.
42. Mok S, Bell D, Knapp R, Fishbaugh P, Welch W, Muto M, et al. Mutation of K-ras protooncogene in human ovarian epithelial tumors of borderline malignancy. Cancer Res 1993;53:1489-92.
43. Ichikawa Y, Nishida M, Suzuki H, Yoshida S, Tsunoda H, Kubo T, et al. Mutation of K-ras protooncogene is associated with histological subtypes in human mucinous ovarian tumors. Cancer Res 1994;54:33-5.
44. Tashiro H, Miyazaki K, Okamura H, Iwai W, Fukomoto M. c-myc over-expression in human primary ovarian tumours: its relevance to tumour progression. Int J Cancer 1992; 50:828-33.